Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors.

Literature DB >> 28425764

BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors.

Abstract

We present a patient with BRAF-V600E mutant papillary craniopharyngioma successfully treated with combination BRAF (dabrafenib 150 mg twice daily) and MEK (trametinib 2 mg daily) inhibitors after her unresectable tumor proved refractory to radiation. Serial brain MRIs and PET revealed marked tumor reduction with gradual neurological improvement and permanent panhypopituitarism.

Entities: Chemical Disease Gene Mutation Species

Keywords: BRAF V600E; craniopharyngioma; dabrafenib; trametinib

Mesh：

Substances：

Year: 2017 PMID： 28425764 PMCID： PMC6020871 DOI： 10.2217/cns-2016-0034

Source DB: PubMed Journal: CNS Oncol ISSN： 2045-0907

10 in total

1. Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations.

Authors: Shigeki Sekine; Tatsuhiro Shibata; Akiko Kokubu; Yukio Morishita; Masayuki Noguchi; Yukihiro Nakanishi; Michiie Sakamoto; Setsuo Hirohashi
Journal: Am J Pathol Date: 2002-12 Impact factor: 4.307

2. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.

Authors: Jean Jacques Grob; Mayur M Amonkar; Boguslawa Karaszewska; Jacob Schachter; Reinhard Dummer; Andrzej Mackiewicz; Daniil Stroyakovskiy; Kamil Drucis; Florent Grange; Vanna Chiarion-Sileni; Piotr Rutkowski; Mikhail Lichinitser; Evgeny Levchenko; Pascal Wolter; Axel Hauschild; Georgina V Long; Paul Nathan; Antoni Ribas; Keith Flaherty; Peng Sun; Jeffrey J Legos; Diane Opatt McDowell; Bijoyesh Mookerjee; Dirk Schadendorf; Caroline Robert
Journal: Lancet Oncol Date: 2015-10 Impact factor: 41.316

3. Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors: Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal: N Engl J Med Date: 2010-08-26 Impact factor: 91.245

Review 4. Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up.

Authors: N Karavitaki; C Brufani; J T Warner; C B T Adams; P Richards; O Ansorge; B Shine; H E Turner; J A H Wass
Journal: Clin Endocrinol (Oxf) Date: 2005-04 Impact factor: 3.478

5. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

Authors: David M Hyman; Igor Puzanov; Vivek Subbiah; Jason E Faris; Ian Chau; Jean-Yves Blay; Jürgen Wolf; Noopur S Raje; Eli L Diamond; Antoine Hollebecque; Radj Gervais; Maria Elena Elez-Fernandez; Antoine Italiano; Ralf-Dieter Hofheinz; Manuel Hidalgo; Emily Chan; Martin Schuler; Susan Frances Lasserre; Martina Makrutzki; Florin Sirzen; Maria Luisa Veronese; Josep Tabernero; José Baselga
Journal: N Engl J Med Date: 2015-08-20 Impact factor: 91.245

6. Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.

Authors: Priscilla K Brastianos; Ganesh M Shankar; Corey M Gill; Amaro Taylor-Weiner; Naema Nayyar; David J Panka; Ryan J Sullivan; Dennie T Frederick; Malak Abedalthagafi; Pamela S Jones; Ian F Dunn; Brian V Nahed; Javier M Romero; David N Louis; Gad Getz; Daniel P Cahill; Sandro Santagata; William T Curry; Fred G Barker
Journal: J Natl Cancer Inst Date: 2015-10-23 Impact factor: 13.506

7. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.

Authors: Priscilla K Brastianos; Amaro Taylor-Weiner; Peter E Manley; Robert T Jones; Dora Dias-Santagata; Aaron R Thorner; Michael S Lawrence; Fausto J Rodriguez; Lindsay A Bernardo; Laura Schubert; Ashwini Sunkavalli; Nick Shillingford; Monica L Calicchio; Hart G W Lidov; Hala Taha; Maria Martinez-Lage; Mariarita Santi; Phillip B Storm; John Y K Lee; James N Palmer; Nithin D Adappa; R Michael Scott; Ian F Dunn; Edward R Laws; Chip Stewart; Keith L Ligon; Mai P Hoang; Paul Van Hummelen; William C Hahn; David N Louis; Adam C Resnick; Mark W Kieran; Gad Getz; Sandro Santagata
Journal: Nat Genet Date: 2014-01-12 Impact factor: 38.330

8. Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor.

Authors: Simon J B Aylwin; Istvan Bodi; Ronald Beaney
Journal: Pituitary Date: 2016-10 Impact factor: 4.107

9. Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles.

Authors: Annett Hölsken; Martin Sill; Jessica Merkle; Leonille Schweizer; Michael Buchfelder; Jörg Flitsch; Rudolf Fahlbusch; Markus Metzler; Marcel Kool; Stefan M Pfister; Andreas von Deimling; David Capper; David T W Jones; Rolf Buslei
Journal: Acta Neuropathol Commun Date: 2016-02-29 Impact factor: 7.801

10. High frequency of BRAF V600E mutations in ameloblastoma.

Authors: Kari J Kurppa; Javier Catón; Peter R Morgan; Ari Ristimäki; Blandine Ruhin; Jari Kellokoski; Klaus Elenius; Kristiina Heikinheimo
Journal: J Pathol Date: 2014-01-31 Impact factor: 7.996

10 in total

22 in total

Review 1. Can tissue biomarkers reliably predict the biological behavior of craniopharyngiomas? A comprehensive overview.

Authors: Ruth Prieto; José M Pascual
Journal: Pituitary Date: 2018-08 Impact factor: 4.107

Review 2. Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?

Authors: Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal: Endocr Pathol Date: 2021-01-12 Impact factor: 3.943

Review 3. The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients.

Authors: Craig Horbinski; Keith L Ligon; Priscilla Brastianos; Jason T Huse; Monica Venere; Susan Chang; Jan Buckner; Timothy Cloughesy; Robert B Jenkins; Caterina Giannini; Roger Stupp; L Burt Nabors; Patrick Y Wen; Kenneth J Aldape; Rimas V Lukas; Evanthia Galanis; Charles G Eberhart; Daniel J Brat; Jann N Sarkaria
Journal: Neuro Oncol Date: 2019-12-17 Impact factor: 12.300

4. Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations.

Authors: Tareq A Juratli; Pamela S Jones; Nancy Wang; Megha Subramanian; Simon J B Aylwin; Yazmin Odia; Elham Rostami; Olafur Gudjonsson; Brian L Shaw; Daniel P Cahill; Evanthia Galanis; Fred G Barker; Sandro Santagata; Priscilla K Brastianos
Journal: Cancer Date: 2019-07-17 Impact factor: 6.860

5. Immunohistochemistry or Molecular Analysis: Which Method Is Better for Subtyping Craniopharyngioma?

Authors: Noriaki Fukuhara; Takeo Iwata; Naoko Inoshita; Katsuhiko Yoshimoto; Masanobu Kitagawa; Hirokazu Fukuhara; Keita Tatsushima; Mitsuo Yamaguchi-Okada; Akira Takeshita; Junko Ito; Yasuhiro Takeuchi; Shozo Yamada; Hiroshi Nishioka
Journal: Endocr Pathol Date: 2020-09-23 Impact factor: 3.943

10. Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature.

Authors: R Borrill; E Cheesman; S Stivaros; I D Kamaly-Asl; K Gnanalingham; John-Paul Kilday
Journal: Childs Nerv Syst Date: 2018-08-01 Impact factor: 1.475